Royalty Pharma Reveals $500 Million R&D Co-Funding Partnership with Johnson & Johnson for 2026-2027
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 30 2026
0mins
Should l Buy JNJ?
Source: moomoo
Funding Announcement: Royalty Pharma has announced a $500 million R&D co-funding agreement with Johnson & Johnson for the years 2026-2027.
Collaboration Details: The agreement aims to support the development of innovative therapies and enhance research capabilities between the two companies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 224.200
Low
190.00
Averages
218.50
High
240.00
Current: 224.200
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
J&J - CAPLYTA Shows Complete Likelihood of Outperforming All Comparators in Mean Weight Change
- J&J's Superiority: J&J has a 100% probability of superior outcomes in mean weight change compared to all competitors.
- Market Position: This statistic highlights J&J's strong position in the market regarding weight management solutions.
See More
J&J - CAPLYTA Demonstrates No Weight Gain Relative to Placebo and Antidepressant Treatment
J&J's Recent Performance: J&J has shown a notable increase in its stock performance compared to its competitors, particularly in the healthcare sector.
Market Comparison: The company's gains are being compared to those of Placebo Plus and Antidepressant Therapy, highlighting its competitive edge in the market.
See More
CAPLYTA® (LUMATEPERONE) DEMONSTRATED THE MOST SIGNIFICANT IMPROVEMENT IN KEY EFFICACY MEASURES AMONG ADJUNCTIVE TREATMENTS FOR MDD IN RECENT NETWORK META-ANALYSIS
Key Findings: CAPLYTA® (lumateperone) demonstrated significant improvements in key efficacy outcomes among adjunctive MDD treatments in a new network meta-analysis.
Clinical Relevance: The results highlight the effectiveness of CAPLYTA® in enhancing treatment outcomes for patients with major depressive disorder when used alongside other therapies.
See More
Markets Hit New Highs, AI Infrastructure Leads the Charge
- Market Performance: On Tuesday, markets continued to rise without new escalations in the Middle East conflict, with West Texas Intermediate crude down about 4% and the benchmark 10-year Treasury yield slightly lower, indicating increased investor confidence in the market.
- Tech Stocks Lead: Chipmakers like Intel, SanDisk, and Micron saw double-digit percentage gains, driving a strong overall performance for technology stocks, with Amazon, Broadcom, Alphabet, and Qnity hitting new 52-week highs, reflecting robust performance in AI-related stocks.
- Strong Earnings Boost Materials: The materials sector emerged as the top performer in the S&P 500, with DuPont being the biggest mover due to its strong earnings report, highlighting investor confidence and interest in the materials industry.
- Robotic Surgery System Progress: Johnson & Johnson announced that its Ottava robotic surgery system achieved primary endpoints in clinical studies for Roux-en-Y gastric bypass procedures, which is expected to support FDA approval for multiple upper abdominal surgeries, further solidifying its position in the robotic surgery market.
See More
Johnson & Johnson's Ottava Surgical System Gains FDA Attention
- Clinical Trial Success: In the FORTE trial, 30 patients underwent Roux-en-Y gastric bypass surgery, achieving an average weight loss of 30 pounds (approximately 13.6 kg) within 30 days post-surgery, demonstrating that the Ottava system meets all safety and performance benchmarks, thereby enhancing its market competitiveness.
- De Novo Application Progress: Johnson & Johnson is seeking De Novo classification from the FDA for the Ottava system, which, if successful, would allow its use in various gastrointestinal surgeries, further expanding its application scope in the medical device market.
- Integration Advantage: The Ottava system is designed to integrate with existing hospital infrastructures, and J&J's CSO Peter Schulam noted that this could eliminate practical barriers for smaller healthcare facilities to adopt robotic surgeries, thus promoting industry growth.
- Market Competition Landscape: As robotic surgeries gain traction, J&J's continued innovation, exemplified by the 510(k) clearance for its MONARCH QUEST device in 2025, indicates its strategy to capture a share of the market dominated by competitors like Intuitive Surgical.
See More
IWD ETF 52-Week High and Low Analysis
- 52-Week Price Range: The IWD ETF has a 52-week low of $182.36 and a high of $232.2595, with the latest trade at $231.82, indicating the ETF is trading near its high, which may attract investor interest in its price movements.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average can provide valuable insights for investors, helping to assess market trends and potential buying opportunities.
- ETF Unit Trading Mechanism: ETFs trade similarly to stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows or outflows, allowing investors to evaluate the impact on underlying assets and make more informed decisions.
See More
J&J - CAPLYTA Shows Complete Likelihood of Outperforming All Comparators in Mean Weight Change
- J&J's Superiority: J&J has a 100% probability of superior outcomes in mean weight change compared to all competitors.
- Market Position: This statistic highlights J&J's strong position in the market regarding weight management solutions.
See More
J&J - CAPLYTA Demonstrates No Weight Gain Relative to Placebo and Antidepressant Treatment
J&J's Recent Performance: J&J has shown a notable increase in its stock performance compared to its competitors, particularly in the healthcare sector.
Market Comparison: The company's gains are being compared to those of Placebo Plus and Antidepressant Therapy, highlighting its competitive edge in the market.
See More
CAPLYTA® (LUMATEPERONE) DEMONSTRATED THE MOST SIGNIFICANT IMPROVEMENT IN KEY EFFICACY MEASURES AMONG ADJUNCTIVE TREATMENTS FOR MDD IN RECENT NETWORK META-ANALYSIS
Key Findings: CAPLYTA® (lumateperone) demonstrated significant improvements in key efficacy outcomes among adjunctive MDD treatments in a new network meta-analysis.
Clinical Relevance: The results highlight the effectiveness of CAPLYTA® in enhancing treatment outcomes for patients with major depressive disorder when used alongside other therapies.
See More
Markets Hit New Highs, AI Infrastructure Leads the Charge
- Market Performance: On Tuesday, markets continued to rise without new escalations in the Middle East conflict, with West Texas Intermediate crude down about 4% and the benchmark 10-year Treasury yield slightly lower, indicating increased investor confidence in the market.
- Tech Stocks Lead: Chipmakers like Intel, SanDisk, and Micron saw double-digit percentage gains, driving a strong overall performance for technology stocks, with Amazon, Broadcom, Alphabet, and Qnity hitting new 52-week highs, reflecting robust performance in AI-related stocks.
- Strong Earnings Boost Materials: The materials sector emerged as the top performer in the S&P 500, with DuPont being the biggest mover due to its strong earnings report, highlighting investor confidence and interest in the materials industry.
- Robotic Surgery System Progress: Johnson & Johnson announced that its Ottava robotic surgery system achieved primary endpoints in clinical studies for Roux-en-Y gastric bypass procedures, which is expected to support FDA approval for multiple upper abdominal surgeries, further solidifying its position in the robotic surgery market.
See More
Johnson & Johnson's Ottava Surgical System Gains FDA Attention
- Clinical Trial Success: In the FORTE trial, 30 patients underwent Roux-en-Y gastric bypass surgery, achieving an average weight loss of 30 pounds (approximately 13.6 kg) within 30 days post-surgery, demonstrating that the Ottava system meets all safety and performance benchmarks, thereby enhancing its market competitiveness.
- De Novo Application Progress: Johnson & Johnson is seeking De Novo classification from the FDA for the Ottava system, which, if successful, would allow its use in various gastrointestinal surgeries, further expanding its application scope in the medical device market.
- Integration Advantage: The Ottava system is designed to integrate with existing hospital infrastructures, and J&J's CSO Peter Schulam noted that this could eliminate practical barriers for smaller healthcare facilities to adopt robotic surgeries, thus promoting industry growth.
- Market Competition Landscape: As robotic surgeries gain traction, J&J's continued innovation, exemplified by the 510(k) clearance for its MONARCH QUEST device in 2025, indicates its strategy to capture a share of the market dominated by competitors like Intuitive Surgical.
See More
IWD ETF 52-Week High and Low Analysis
- 52-Week Price Range: The IWD ETF has a 52-week low of $182.36 and a high of $232.2595, with the latest trade at $231.82, indicating the ETF is trading near its high, which may attract investor interest in its price movements.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average can provide valuable insights for investors, helping to assess market trends and potential buying opportunities.
- ETF Unit Trading Mechanism: ETFs trade similarly to stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows or outflows, allowing investors to evaluate the impact on underlying assets and make more informed decisions.
See More
